BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform Vancouver, British Columbia – (December 1st, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its […]
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Next-generation metabolomics and AI technology supports the 2026 – 2035 Pan-Canadian Lung Cancer Action Plan’s call to expand equitable access to life-saving early diagnosis Vancouver, British Columbia – (November 12, 2025) – November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy […]
BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial Extensive Validation of BioMark’s Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network. Vancouver, British Columbia – (October 7, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a […]
BioMark Secures Key Patents in Asia’s Largest Markets for Early Lung Cancer Liquid Biopsy
BioMark Secures Key Patents in Asia’s Largest Markets for Early Lung Cancer Liquid Biopsy Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets. Vancouver, British Columbia – (September 29, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading […]
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets Vancouver, British Columbia – (August 12, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, announced […]
Press Release – BioMark Diagnostics Announces Expansion of its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
Press Release – BioMark Diagnostics Announces Expansion of its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay Vancouver, British Columbia – (August 5, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a […]
Press Release – BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 – 2026
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 – 2026 VANCOUVER, BC – (July 30, 2025) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today announced a summary of its fiscal year […]
Press Release – BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia – (May 20, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of […]
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of its Early-Stage Lung Cancer Test
Study Published in a special issue of International Journal of Molecular Sciences Confirms Test’s Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British Columbia – (May 12, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today […]
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia – (May 8th, 2025) BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have […]